Galenica earnings calendar sets the tone, shares tracked on SIX Swiss Exchange

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-23, 23:14.

Galenica (CH0025536027) stands in focus for Swiss healthcare investors as the group approaches its next earnings window on SIX Swiss Exchange. The stock sits in the defensive healthcare and retail pharmacy segment alongside peers such as Zur Rose and Novartis.

What the schedule shows

According to the company’s financial calendar, Galenica plans to present its half-year 2026 results in late summer, following the publication of its full-year 2025 figures on 12 March 2026. The March results release confirmed ongoing execution of its Omnichannel healthcare strategy and store network optimization per the company’s investor publications.

The group also scheduled its 2026 annual general meeting in April 2026 in Bern, where shareholders voted on the dividend and board elections. Swiss investors on SIX typically watch these dates closely to position around dividend payments and potential communication on medium-term guidance, as is standard practice among SMI-related healthcare names such as Novartis and Roche.

Analysts’ view on Galenica

On the analyst side, data compiled by MarketScreener show that a majority of covering banks including Zürcher Kantonalbank and UBS rate Galenica between Hold and Buy, with a consensus 12-month target price sitting moderately above the current share price level. The aggregated consensus also points to a mid-single-digit percentage revenue increase and stable EBITDA margin for 2026, according to the latest MarketScreener consensus overview.

Analysts typically highlight the company’s resilient cash generation from its Swiss pharmacy and wholesale activities, while flagging regulatory risk around drug pricing. In line with other Swiss healthcare distributors, the stock is commonly viewed as a defensive holding relative to more volatile biotech names on SIX Swiss Exchange.

How Galenica earns its money

Galenica generates most of its revenue from its Swiss pharmacy networks and healthcare logistics activities, including the Amavita and Sun Store pharmacy brands and the Galexis wholesale operations. The group also operates specialty pharmacy formats and digital health services targeting chronic patients and prescription management in Switzerland.

Where the stock trades today

The Galenica shares (CH0025536027) last traded on SIX Swiss Exchange at 0.00 Swiss francs as of 2026-06-23, 23:00.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.